Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbolevure is an oral combination drug product developed by Pierre Fabre Médicament for the symptomatic treatment of digestive disorders. It contains two active components: activated charcoal, which acts as an adsorbent to capture gases and toxins within the gastrointestinal tract, and live dehydrated yeast (*Saccharomyces cerevisiae*), which serves as a probiotic to restore and maintain the balance of intestinal flora. The medication is primarily indicated for intestinal gas-related issues such as bloating, flatulence, and diarrhea, including those associated with antibiotic use. It is available in capsule form for both adults and children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Carbolevure.